Arca
Skip to content
Tools
Tools

MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases.

  • Drugs that act on it: 15
  • Approved: 4
  • In phases 1 to 3: 11
  • Sponsors: 9

Who Is On It, and How Far Along

Every drug ChEMBL records acting on MAP2K2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Other

Approved4

  • Trametinib
  • Binimetinib
  • Selumetinib
  • Cobimetinib

Phase 31

  • Avutometinib

Phase 26

  • Mirdametinib
  • Balamapimod
  • CI-1040
  • Pimasertib
  • Refametinib
  • TAK-733

Phase 14

  • AS-703988
  • AZD-8330
  • RO-4987655
  • WX-554

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule1387%
  • Other213%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Dual specificity mitogen-activated protein kinase kinase 2 inhibitor.
TrametinibApprovedNovartis PharmaceuticalsSmall moleculeInhibitor—106—
BinimetinibApprovedPfizerSmall moleculeInhibitor—44—
SelumetinibApprovedAstraZeneca PharmaceuticalsSmall moleculeInhibitor—40—
CobimetinibApprovedRocheSmall moleculeInhibitor—30—
AvutometinibPhase 3VerastemSmall moleculeInhibitor—22—
MirdametinibPhase 2Merck KGaASmall moleculeInhibitor—17—
BalamapimodPhase 2—Small moleculeInhibitor—0—
CI-1040Phase 2PfizerSmall moleculeInhibitor—0—
PimasertibPhase 2Merck KGaASmall moleculeInhibitor—0—
RefametinibPhase 2BayerSmall moleculeInhibitor—0—
TAK-733Phase 2Takeda Pharmaceuticals USASmall moleculeInhibitor—0—
AS-703988Phase 1Merck KGaAOtherInhibitor—0—
AZD-8330Phase 1AstraZeneca PharmaceuticalsSmall moleculeInhibitor—0—
RO-4987655Phase 1RocheSmall moleculeInhibitor—0—
WX-554Phase 1Heidelberg Pharma AGOtherInhibitor—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 48 in all, from ClinicalTrials.gov.
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young AdultsMirdametinibPhase 2Not yet recruitingNational Cancer Institute (NCI)2026-10-23
A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsTrametinibPhase 1 / Phase 2Enrolling by invitationSecond Affiliated Hospital of Wenzhou Medical University2026-10-22
Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN)Selumetinib—RecruitingAstraZeneca2026-10-22
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerTrametinibPhase 2Not yet recruitingWashington University School of Medicine2026-10-21
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral MelanomaTrametinibPhase 4Not yet recruitingPeking University Cancer Hospital & Institute2026-10-02
A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasMirdametinibPhase 1Not yet recruitingSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany2026-09-30
A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy ParticipantsMirdametinibPhase 1RecruitingMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany2026-09-25
Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic AdenocarcinomaAvutometinibPhase 1 / Phase 2Not yet recruitingUniversity of Virginia2026-09-17
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERITTrametinibPhase 3Not yet recruitingCarelon Research2026-09-14
Molecularly Tailored Therapy in Advanced Pancreatic CancerTrametinibPhase 2Not yet recruitingHerlev Hospital2026-09-03
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade GliomasAvutometinibEarly phase 1Not yet recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins2026-08-21
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) PatientsTrametinib—Not yet recruitingNovartis Pharmaceuticals2026-08-18
A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesTrametinib—Not yet recruitingNovartis Pharmaceuticals2026-08-17
Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)AvutometinibPhase 2Not yet recruitingVerastem, Inc.2026-08-05
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorAvutometinibPhase 2Not yet recruitingGirish Dhall, MD2026-08-04
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)SelumetinibPhase 2Not yet recruitingBeijing Tiantan Hospital2026-07-20
Selumetinib for NF2-Related SchwannomatosisSelumetinibPhase 2Not yet recruitingBeijing Tiantan Hospital2026-07-16
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaSelumetinibPhase 1 / Phase 2RecruitingNational Cancer Institute (NCI)2026-06-02
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAsTrametinibPhase 2RecruitingChildren's Hospital of Philadelphia2026-04-24
A Study of Mirdametinib in People With Central Nervous System TumorsMirdametinibPhase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer Center2026-04-20
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade GliomaMirdametinibPhase 2Not yet recruitingUniversity of Alabama at Birmingham2026-04-13
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaCobimetinibPhase 2RecruitingHanmi Pharmaceutical Company Limited2026-03-04
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasCobimetinib—Active, not recruitingBlokhin's Russian Cancer Research Center2026-03-04
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerAvutometinibPhase 1RecruitingM.D. Anderson Cancer Center2026-01-06
Mirdametinib in Patients With Advanced NF1-mutant MelanomaMirdametinibPhase 2RecruitingKevin Kim, MD2025-11-19
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaAvutometinibPhase 2RecruitingWashington University School of Medicine2025-08-17
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic LeukemiaMirdametinibPhase 2RecruitingNational Cancer Institute (NCI)2025-07-14
UK ENcorafenib and BInimetinib Real-world Study in MelanomaBinimetinib—Active, not recruitingPierre Fabre Ltd2025-06-15
Effect of Hepatic Impairment on the Pharmacokinetics of MirdametinibMirdametinibPhase 1RecruitingSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany2025-05-30
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain MetastasesBinimetinibPhase 2RecruitingGrupo Español Multidisciplinar de Melanoma2025-03-20
Using Tumor Models to Determine TreatmentsCobimetinibPhase 2RecruitingUniversity Health Network, Toronto2025-02-06
Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic MelanomaBinimetinib—RecruitingAssistance Publique - Hôpitaux de Paris2025-01-14
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese ChildrenSelumetinibPhase 2Not yet recruitingWest China Hospital2025-01-08
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNSTSelumetinibPhase 1 / Phase 2RecruitingAeRang Kim2024-12-16
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsAvutometinibPhase 2Active, not recruitingVerastem, Inc.2024-11-12
5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursAvutometinibPhase 1 / Phase 2RecruitingInstitute of Cancer Research, United Kingdom2024-10-08
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate CapsuleSelumetinibPhase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2024-10-01
The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate CapsuleSelumetinibPhase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2024-10-01
Circulating Tumour DNA Guided Adaptive BRAF and MEK Inhibitor TherapyBinimetinibPhase 2Not yet recruitingThe Christie NHS Foundation Trust2024-06-24
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationCobimetinibPhase 2RecruitingCity of Hope Medical Center2024-06-04
Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal CancerBinimetinibPhase 2RecruitingSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)2024-01-17
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic CancerBinimetinibPhase 2RecruitingNational Cancer Center, Japan2023-12-06
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.CobimetinibPhase 2 / Phase 3RecruitingCancer Research UK2023-03-14
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolCobimetinibPhase 2 / Phase 3RecruitingCancer Research UK2023-02-10
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersCobimetinibPhase 1Active, not recruitingNational Cancer Institute (NCI)2023-01-20
Personalized Medicine for Advanced Biliary Cancer PatientsBinimetinibPhase 3RecruitingUNICANCER2022-11-14
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)BinimetinibPhase 2Active, not recruitingNational Cancer Institute (NCI)2022-10-03
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsCobimetinibPhase 2RecruitingHelsinki University Central Hospital2021-12-16

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Cardiofaciocutaneous syndrome
0.86
Cancer
0.66
Noonan syndrome
0.65
RASopathy
0.57
Neurofibromatosis type 1
0.56
Neoplasm
0.56
Metastatic melanoma
0.53
Plexiform neurofibroma
0.51
Costello syndrome
0.51
Low grade glioma
0.49

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
MAP2K2

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2964, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P36507, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.